Arrowhead Pharmaceuticals, Inc. today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company's investigational RNA interference (RNAi) therapeutic targeting complement ...
Quad/Graphics, Inc. ("Quad" or the "Companxy"), a global marketing experience company, today announced that S&P Global Ratings ("S&P") upgraded its issuer credit rating for Quad to 'BB-' from 'B+' ...
Egbin Power has once again demonstrated its commitment to ensuring healthy lives and well-being of its communities by offering free medical services to ...